HOMOGENEOUS HEMAGGLUTINATION ASSAY FOR HIV

HIV 均相血凝试验

• 批准号: 2522844
• 负责人: JAMES W LARRICK
• 金额: $ 10万
• 依托单位: PANORAMA RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-03-01 至 1998-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2522844
• 关键词: antiviral antibody; bacteriophage M13; biomarker; communicable disease diagnosis; diagnosis design /evaluation; erythrocytes; genetic library; hemagglutination test; human immunodeficiency virus 1; recombinant virus; virus protein

DESCRIPTION: The overall goal of this project is to construct recombinant filamentous bacteriophages to be directly used as reagents in diagnostic hemagglutination assays. The M13 phage will be engineered to express antibody to a conserved cell surface marker on human erythrocytes (GFA) and a peptide from HIV-1. When these recombinant phage are placed in direct contact with a blood sample from an HIV-1- infected individual, erythrocyte agglutination will be induced by anti- antigen antibodies present in the serum, that will bridge the phage particles attached to different red blood cells. In phase 1, a M13 phage expressing anti-GFA antibody and HIV peptide will be constructed, and a assay will be developed using known antibodies and sera from HIV-1 infected individuals. In phase II, the sensitivity and specificity of the assay will be determined. Successful demonstration of this method will provide a rapid, inexpensive assay for HIV and other infectious diseases. PROPOSED COMMERCIAL APPLICATION: Proposed commercial application not available.

描述：该项目的总体目标是建立 直接用作试剂的重组丝状噬菌体 在诊断性血凝试验中。 M13噬菌体将被改造成 为了表达针对人细胞表面保守的细胞表面标记的抗体， 红细胞（GFA）和来自HIV-1的肽。 当这些重组 将噬菌体置于与来自HIV-1的血液样品直接接触， 受感染的个体，红细胞凝集将被抗 存在于血清中的抗原抗体，其将桥接噬菌体 附着在不同红细胞上的微粒 在第一阶段， 构建表达抗GFA抗体和HIV肽的噬菌体， 并将使用已知的HIV-1抗体和血清开发一种检测方法 感染的人。 在第二阶段， 将测定含量。 这种方法的成功示范 将提供一种快速、廉价的艾滋病毒和其他传染性疾病的检测方法， 疾病 拟定商业应用： 未提供拟议的商业应用。